Josep Tabernero
Vall d'Hebron University Hospital (HUVH) · Medical Oncology Department, Vall d'Hebron Institute of Oncology, CIBERONC · Vall d'Hebron Institute of Oncology
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
18
all conditions, ClinicalTrials.gov
NIH grants tied to them
0
NIH RePORTER
Trial papers in pancreatic cancer
15
PubMed author-name match
Trials
Studies that name Josep Tabernero as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:36 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07693751 · A Study to Assess Safety and Efficacy of SOT109 in Patients With Advanced Unresectable or Metastatic Colorectal CancerSOTIO Biotech a.s. · recruiting · Colorectal Cancer (Locally Advanced or Metastatic) · principal investigator
- Ph2NCT05582031 · Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable CancersTranslational Research in Oncology · withdrawn · Anal Squamous Cell Carcinoma, Colorectal Neoplasms, Soft Tissue Sarcoma · study chair
- Ph1/Ph2NCT05525286 · Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic AdenocarcinomaSOTIO Biotech a.s. · terminated · Pancreatic Cancer · principal investigator
- Ph3NCT04737187 · Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer PatientsTaiho Oncology, Inc. · completed · Refractory Metastatic Colorectal Cancer · principal investigator
- Ph1/Ph2NCT04495621 · MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)Menarini Group · completed · Metastatic Colorectal Cancer · study chair
- Ph3NCT03750786 · A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal CancerIsofol Medical AB · completed · Colo-rectal Cancer · principal investigator
- Ph3NCT03717038 · Sym004 Versus TAS-102 in Patients With mCRCSymphogen A/S · withdrawn · Metastatic Colorectal Cancer, Colorectal Cancer Metastatic, Carcinoma · principal investigator
- Ph1NCT03403725 · MEN1309 I.v. Infusion in Pts With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory NHL Ph I StudyMenarini Group · terminated · Metastatic Solid Tumors, Relapsed/Refractory Non-Hodgkin Lymphoma · study chair
- Ph2NCT02982694 · Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal CancerVall d'Hebron Institute of Oncology · terminated · MSI, ColoRectal Cancer, Chemotherapy · principal investigator
- Ph1/Ph2NCT02568046 · Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer PatientsSymphogen A/S · terminated · Metastatic Colorectal Cancer · principal investigator
- Ph2NCT02083653 · Sym004 vs Standard of Care in Subjects With Metastatic Colorectal CancerSymphogen A/S · completed · Metastatic Colorectal Cancer · principal investigator
- Ph1NCT01320020 · A Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer PatientsNeovii Biotech · terminated · Epithelial Cancer Patients · study chair
- Ph1/Ph2NCT01117428 · Sym004 in Patients With Advanced Solid TumorsSymphogen A/S · completed · Metastatic Colorectal Cancer · principal investigator
- Ph2NCT01032291 · A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal CancerCelgene Corporation · terminated · Colorectal Cancer · principal investigator
- Ph1/Ph2NCT01008475 · EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal CancerMerck KGaA, Darmstadt, Germany · completed · Metastatic Colorectal Cancer · principal investigator
- Ph2NCT00958386 · Safety and Efficacy Study of Panitumumab+Irinotecan in Patients Wild-Type (WT) KRAS Metastatic Colorectal Cancer Refractory to Irinotecan Based Chemotherapy (SPECTRA)Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) · completed · Metastatic Colorectal Cancer · study chair
- Ph1NCT00877474 · Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid TumorsPharmaMar · completed · ADVANCED SOLID TUMORS · principal investigator
- Ph2NCT00733889 · A Study to Evaluate the Combination of Cetuximab and Chemotherapy as Neoadjuvant Therapy Followed Concomitant Chemoradiotherapy Plus Cetuximab in Locoregional Esophageal CarcinomaSpanish Cooperative Group for the Treatment of Digestive Tumours (TTD) · completed · Esophageal Carcinoma · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:36 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in pancreatic cancer, ranked by citations from NIH iCite, fetched 2026-11-12 12:36 UTC. The ranking covers the 200 most relevant of 15 PubMed records, and a shared surname and initials can bring in a namesake. All 15 on PubMed
- 5,502 citationsRCR 166.6
- nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.J Natl Cancer Inst · 2015507 citationsRCR 16.5
- 279 citationsRCR 7.4
- Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer.Br J Cancer · 2018264 citationsRCR 8.5
- Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial.J Clin Oncol · 2023135 citationsRCR 12.5
- 119 citationsRCR 4.0
- SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial.Clin Cancer Res · 2015119 citationsRCR 3.6
- 106 citationsRCR 5.1
- 94 citationsRCR 3.3
- TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer.Cancer Chemother Pharmacol · 201989 citationsRCR 3.0